MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
3.050
-0.100
-3.17%
After Hours: 3.060 +0.01 +0.33% 19:34 05/13 EDT
OPEN
3.120
PREV CLOSE
3.150
HIGH
3.150
LOW
3.050
VOLUME
13.61M
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
2.800
MARKET CAP
1.62B
P/E (TTM)
-2.5330
1D
5D
1M
3M
1Y
5Y
1D
Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities
TipRanks · 19h ago
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks
Simply Wall St · 1d ago
Weekly Report: what happened at RXRX last week (0504-0508)?
Weekly Report · 2d ago
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates
Simply Wall St · 4d ago
Recursion director Christopher Gibson disposes of 60,000 shares for $134,800
PUBT · 5d ago
Recursion’s AI Drug Programs Show Early Clinical Progress And Valuation Gap
Simply Wall St · 5d ago
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Seeking Alpha · 5d ago
3 Stocks Poised to Disrupt the Healthcare Market by 2030
The Motley Fool · 5d ago
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.